Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported earnings for its first fiscal quarter (ending March 31) of $6.70 versus $7.64 for the same period a year ago — a decline of -12%. This result fell short of the consensus estimate of $12.04 by $-5.34. For the latest four quarters through March 31, E.P.S. were $36.11 versus $39.04 for the same period a year ago — a decline of -8%.
Recent Price Action
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock enjoyed a large increase of 3.8% on 5/2/24. The stock closed at $937.61. Moreover, exceptionally high trading volume at 227% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 3.4% during the last week.
Current PriceTarget Research Rating
REGN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Regeneron Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a slightly positive Appreciation Score of 67 and a good Power Rating of 71, with the Positive Value Trend Rating the result.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment